Comparison of efficacy, side effects, and patient satisfaction in patients with limited scalp areata alopecia in a multiple group study with Latanoprost, Minoxidil, and Betamethasone
Phase 3
Recruiting
- Conditions
- alopecia areata.Alopecia areata
- Registration Number
- IRCT20211109053013N1
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 108
Inclusion Criteria
Patients with localized areata alopecia of beard or scalp (<3 patches)
Not receiving any medication for areata alopecia for at least 1 month before the beginning of the study
Signing an informed written consent
Exclusion Criteria
Patients with extensive alopecia (> 3 patches)
Patients with any systemic disorder , ophthalmic pathology, other dermatological diseases, skin atrophy, or infection at the alopecic region
Patients with allergy or hypersensitivity to any component of the treatment products
Pregnant and lactating women
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The severity of alopecia was determined by the severity of alopecia tool (SALT) score before and after therapy. Scalp hair loss grading will be as below: S0=no hair loss; S1 < 25% hair loss; S2 =25–49%hair loss; S3=50–74% hair loss; S4=75–99% hair loss and S5=100% hair loss. Grades of body hair loss included: B0, nobody hair loss; B1, some body hair loss, and B2, 100% body(excluding scalp) hair loss. Timepoint: Calculation of SALT score at the beginning of the study (before the intervention) and 2 and 6 weeks after treatment begins. Method of measurement: Regrowth was calculated as [(SALT score at base line-SALTscore at follow-up)/SALT score at base line] 100 and was categorized as A0= no change or further loss, A1=1–24% regrowth, A2=25–49% regrowth, A3=50–74% regrowth, A4=75–99%regrowth and A5=100% regrowth.
- Secondary Outcome Measures
Name Time Method Patients' satisfaction of treatment. Timepoint: At the beginning of the study (before the intervention) and 2 and 6 weeks after treatment begins. Method of measurement: By using a questionnaire: (1= no response, 2=fair improvement,3=good improvement, 4=very good improvement and 5=excellent improvement).